KLRK1 and cancer: Because HDAC inhibitors are known potent inducers of NKG2D ligands on many cancer cells [14,15], it is possible that the induced NKG2D ligands could overcome immune tolerance and make cancer cells sensitive to NK-cell mediated cytotoxicity.